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The mortality in Germany caused by the 2009 pan-
demic influenza A(H1N1) seems to have been one of 
the lowest in Europe. We provide a detailed analysis 
of all 252 fatal cases of confirmed infection with the 
pandemic virus notified between 29 April 2009 and 31 
March 2010. The overall mortality was 3.1 (95% confi-
dence interval (CI): 2.7 to 3.5) per one million inhab-
itants. We observed an increase in the case fatality 
rate of notified cases over time; notified cases aged 
60 years or older had the highest case fatality rate 
(2.16%; 95% CI: 1.61 to 2.83; odds ratio: 5.4; p<0.001; 
reference group: 35–59 years). The median delay of 
four days (interquartile range (IQR): 2–7) between 
symptom onset and antiviral treatment was signifi-
cantly longer in fatal cases than for non-fatal cases 
(median: two days (IQR: 1–3; p<0.001). Analysis of the 
underlying medical conditions of fatal cases, based on 
the observed frequency of the conditions in the gen-
eral population, confirms the risk for fatal outcome, 
which is most notably due to immunosuppression, 
diabetes and respiratory diseases. Our results sug-
gest that early treatment might have had an impact on 
overall mortality. Identification of risk groups for tar-
geted intervention to prevent fatalities needs to take 
into account the distribution of underlying conditions 
in the population.
Introduction
Based on initial reports from Mexico, the case fatal-
ity rate (CFR) of 2009 pandemic influenza A(H1N1) was 
estimated to be 0.09% (range: 0.07–0.4) and there was 
considerable uncertainty over what could be expected 
in other countries [1]. Since March 2009, various coun-
tries in Europe and worldwide have experienced one or 
more pandemic waves, with remarkable differences in 
the number of reported deaths between countries [2-9]. 
On 27 April 2009 the first symptomatic cases positive 
for the pandemic virus were notified in Germany [10]. 
The first death associated with laboratory-confirmed 
pandemic influenza was reported on 25 September 
2009 from North Rhine-Westphalia, just before the 
number of autochthonous cases started to rise expo-
nentially in week 42 [11,12]. Despite more than 200,000 
cases of laboratory-confirmed pandemic influenza, 
the overall mortality in Germany based on the noti-
fied cases is one of the lowest in Europe. However, an 
intriguing number of deaths occurred after the inci-
dence of influenza at the population level had already 
subsided at the end of 2009.
This article presents a detailed analysis of all 252 noti-
fied fatal cases in Germany, from the first detection 
of pandemic cases in April 2009 up to 31 March 2010. 
We focused on the course of disease, antiviral treat-
ment and the risk factors involved in order to better 
understand how the situation in Germany differed from 
that in other countries and to identify groups at risk of 
severe disease and fatal outcome, in preparation for 
potential subsequent waves.
Methods
In Germany, in accordance with the protection against 
infection act, every laboratory-confirmed case of influ-
enza has to be notified by the laboratory to the local 
health authority and additional clinical information is 
actively retrieved from the physician [13]. Additionally, 
on 2 May 2009, a special legal ordinance for pandemic 
influenza came into force. German physicians had to 
notify suspected cases of pandemic influenza to the 
local health authorities. For this the case ascertain-
ment followed the recommendations given by the pro-
fessional medical societies [12,14]. Suspected cases 
were tested for presence of the pandemic virus and 
only laboratory-confirmed cases or clinical cases with 
an epidemiological link to a laboratory-confirmed case 
were transmitted for whole Germany from the local 
health authorities via the federal states to the Robert 
Koch Institute in Berlin, Germany. These cases are 
included in this study. 
A fatal case is defined as a person whose death was 
in temporal relation to an infection with pandemic 
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influenza confirmed by direct identification tests 
using standard laboratory methods (polymerase chain 
reaction (PCR) or viral culture) irrespective of other 
diagnoses. Laboratory confirmation could be ante- or 
post-mortem. Proof of a causal relationship between 
death and laboratory-confirmed influenza was not 
established. All cases (fatal and non-fatal) are trans-
mitted  using the official electronic notifying system 
in Germany (SurvNet) [15]. The system includes infor-
mation on age, date of onset of illness, hospitalisation 
and fatal outcome. It allows the update of information 
including additions and corrections.
Starting on 17 July 2009, the following additional case-
based information was included for all notified and 
transmitted cases, using a standardised free-text for-
mat: antiviral treatment (none; oseltamivir; zanamivir), 
date of start of treatment, reason for hospitalisation 
(Influenza; other disease, unknown), pneumonia (yes; 
no) and underlying chronic medical disease conditions 
(none; diabetes mellitus; impairment of the cardio-
vascular system including hypertension; impairment 
of the respiratory system; obesity defined as a body 
mass index (BMI)>30; pregnancy; immunosuppression; 
other specified). Data sets of fatal cases in the central 
database at the Robert Koch Institute were addition-
ally checked for possible inconsistencies and only vali-
dated data sets were included in the analysis. A more 
detailed description of the special issues concerning 
German data acquisition during the pandemic has been 
published recently [12].
Cross-sectional data on the 12-monthly prevalence 
for chronic disease conditions in Germany was col-
lected via a telephone-based self-reported survey – 
Gesundheit in Deutschland Aktuell [German Health 
Update]. For detailed information on the method, see 
reference 16. The target population was the German-
speaking resident population aged 18 years and above. 
The current survey was conducted from July 2008 to 
June 2009, covering the start of the pandemic. 
The overall mortality for Germany is based on the total 
population in 2009 reported by the Federal Statistical 
Office (82,200,000) and we calculated cumulative mor-
tality stratified by age group. For the comparison of 
mortality between different countries, data provided 
by the European Centre for Disease Prevention and 
Control (ECDC) were used [5]. As denominator, esti-
mates for the total populations of European countries 
were obtained from Eurostat, the United States Census 
Bureau and Statistics Canada (all 2009 estimates).
All calculations were based on cases with available 
information as denominator. To calculate the case fatal-
ity, we used the number of laboratory-confirmed or 
epidemiologically confirmed pandemic influenza cases 
notified in Germany for each week as the denominator. 
Odds ratios (ORs) were given for the influence of age 
group on the incidence of fatal outcome in all notified 
influenza cases. Relative risks (RRs) were calculated as 
risk of death in persons with underlying chronic con-
ditions divided by the risk of death in persons with-
out these reported risk factors; sex and 10 age strata 
were used for adjustment, except for pregnancy. We 
included the exact binomial 95% confidence intervals 
(CIs) for proportions and the test on the equality of 
medians if appropriate. For time spans, the median 
and interquartile range (IQR) as measure of statistical 
dispersion were given. Stata was used for calculations. 
Results 
Disease frequency
In Germany 252 fatal cases associated with labora-
tory-confirmed 2009 pandemic influenza A(H1N1) were 
reported, starting with the first case on 25 September 
2009. The first increase in the number of fatal cases 
occurred in week 44 of 2009 and within one month the 
notification of fatal cases rose to a maximum of 37 (in 
week 47) (Figure 1). A second peak was observed, with 
20 fatal cases per week from week 52 of 2009 to week 
1 of 2010. Taking all notified and transmitted cases as 
the denominator (n=226,075), the overall CFR of noti-
fied cases (nCFR) was calculated to be 0.11% (95% CI: 
0.10 to 0.13). The cumulative mortality by 31 March 
2010 was 3.1 (95% CI: 2.7 to 3.5) per million inhabit-
ants. The majority (58%; 95% CI: 52 to 64) of fatal 
cases was male. In cases aged below 15 years a high 
proportion (66%: 95% CI: 46 to 82) of fatal cases was 
female.
During the pandemic wave, the weekly nCFR changed 
with a period with low values before the calendar 
week 52 and high thereafter (Figure 1). Taking week 
52 as a cut-off date we divided the fatal cases into 
early (n=189) and late cases (n=63). In a univariate 
analysis there was a significant association of the late 
cases with advanced age (≥60 years; p=0.016) and 
being male (p=0.038). Underlying medical risk factors 
(p=0.17), interval between the onset of symptoms and 
death (p=0.56) and the time from onset of symptoms to 
the start of antiviral treatment (p=0.34) were not asso-
ciated with late cases. The multivariate model with the 
above independent variables failed to achieve statisti-
cal significance, but this is probably due to small num-
bers of cases. 
Age distribution
The median age of the fatal cases was 47 years (IQR: 
29–57), which is significantly higher than for the non-
fatal cases (median: 16 years; IQR: 10–28; p<0.001). 
Generally, all age groups were affected: the age group 
with the highest mortality was children aged less than 
1 year with a cumulative mortality of 4.4 (95% CI: 
1.6 to 9.5) per one million children of this age group 
(Table 1), followed by the age group 35–59 years with 
4.2 (95% CI: 3.5 to 5.0) per one million people of this 
age. However, the 95% CIs and the Kruskal–Wallis rank 
test (p=0.41) indicate that differences in mortality 
between the age groups was not pronounced and did 
not achieve statistical significance.
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In contrast, the nCFR was highest in elderly people 
(≥60 years), at 2.16%, with an OR of 5.4 (95% CI: 3.9 
to 7.6) in comparison with the age group 35–59 years. 
Schoolchildren (5–14 years) showed the lowest nCFR of 
0.03% (95% CI: 0.02 to 0.04) with an OR of 0.07 (95% 
CI: 0.04 to 0.12). 
Course of disease
The median interval between the onset of symptoms 
and death was 13 days (IQR: 6–22). Symptom onset in 
adult cases was reported to have occurred more than 
14 days before the date of death for 91 of 233 (39%) 
cases and more than 28 days for 44 of 233 (19%) cases. 
However, this was observed only for adult cases. In 
children (<15 years), this interval was significantly 
shorter, with a median of six days (IQR: 3–13), than in 
the other age groups (p=0.01).
The majority of notified fatal cases (211 of 233, 90.6%) 
had been admitted to a hospital. In 125 of 164 (76.2%) 
cases, the influenza infection was indicated as the 
cause for hospitalisation. The median length of hospi-
talisation overall was 12 days (IQR: 4–23); in children 
(<15 years), the median (five days; IQR: 3–12) was sig-
nificantly shorter than that in the other age groups 
(p=0.04). Pneumonia was diagnosed in 200 of 220 
(90.9%) cases. 
Antiviral treatment
Antiviral therapy was started in more than half of the 
fatal cases (148 of 230; 64.3%), with oseltamivir in 141 
cases and zanamivir in seven cases. In those patients 
with available data, the median time from onset of 
symptoms to the start of antiviral treatment was four 
days (IQR: 2–7) (Figure 2). This interval was signifi-
cantly longer than that for non-fatal cases (two days; 
IQR: 1–3; p<0.001). In 11 of 15 (73.3%) fatal cases below 
15 years of age and in 93 of 125 (74.4%) of the adult 
fatal cases, treatment was not carried out within 48 
hours of the onset of symptoms as recommended [14]. 
The median time from the start of antiviral treatment to 
death was five days (IQR: 2–12). 
Risk factors
At least one risk factor for severe influenza illness was 
present in 200 of the 252 fatal cases (79.4%). More 
than one underlying medical condition was reported 
for 61(24.2%) of the patients. For 34 (13.5%) of the fatal 
cases, no underlying condition regarded as a risk fac-
tor was reported. Of these 34 cases, four were aged 
below 15 years and 13 were female. Half of these cases 
(16 of 32 with available information) had received anti-
viral treatment, which was significantly less often than 
in cases with reported risk factors (p=0.039). 
Figure 1
Notified fatal cases of 2009 pandemic influenza A(H1N1) 
and case fatality rate, by week of symptom onset in 2009 
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Black bars represent 95% confidence intervals.
Table 1










(95% CI)c P value
0–1 6 66 4.4 (1.6–9.5) 0.18 0.47 (0.21–1.06) 0.07
2–4 4 50 1.9 (0.5–4.9) 0.05 0.13 (0.05–0.35) <0.001
5–14 19 21 2.5 (1.5–3.9) 0.03 0.07 (0.04–0.12) <0.001
15–34 42 57 2.2 (1.6–3.0) 0.07 0.18 (0.13–0.26) <0.001
35–59 130 62 4.2 (3.5–5.0) 0.40 Reference group Reference group
≥60 51 63 2.4 (1.8–3.2) 2.16 5.4 (3.86–7.56) <0.001
Total 252 58 3.1 (2.7–3.5) 0.150.11d – –
CI: confidence interval.
a Based on the German population of 2008. The output of the Kruskal–Wallis rank test was p= 0.41, which indicates that there were no 
significant differences in cumulative mortality between the age groups. 
b Denominator: all notified and transmitted pandemic influenza cases with detailed information on age, unless otherwise indicated.
c Odds ratio for the influence of the age group on the incidence of fatal outcome in all pandemic cases. The age group 35–59 years was set as 
the reference group. 
d Denominator: all notified and transmitted pandemic influenza cases. 
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Measures of disease frequency and association with 
underlying medical conditions among adult (≥18 years) 
fatal cases are given in Table 2. The relative risk of 
death of infected individuals with underlying chronic 
disease conditions in comparison with that for infected 
individuals without any reported risk factors was 10.0 
(95% CI: 6.7 to 15.0). Immunosuppression was most 
frequently notified, with a proportion of 26.0% (95% 
CI: 20.0% to 32.7%) fatal cases. This is in keeping with 
the fact that immunosuppression was notified in 34 of 
138 (24.6%) of the fatal cases with only one underlying 
disease as a risk factor. This is by far the highest pro-
portion in this group of patients, indicating a strong 
association to severe cases of pandemic influenza. 
However, no population-based survey data are avail-
able to calculate the relative risk. 
Diseases of the cardiovascular system were reported, 
with a proportion of 23.5% (95% CI: 16.7 to 29.3), 
which is in the same range as the sum of self-reported 
population-based 12-month prevalences of hyperten-
sion: 21.4% (95% CI: 20.9 to 22.0), angina pectoris: 
1.7% (95% CI: 1.5 to 1.9) and heart failure: 2.4% (95% 
CI: 2.2 to 2.6). Obesity was notified with a proportion 
of 19.9% (95% CI: 14.5 to 26.2) and showed a slight 
association with fatal outcome RR: 1.2 (95% CI: 0.8 to 
1.8). Underlying chronic respiratory disease was noti-
fied, with a proportion of 19.9% (95% CI: 14.5 to 26.2). 
This proportion was twice as high as the combined 
prevalence of asthma: 5.2% (95% CI: 4.9 to 5.5) and 
chronic (obstructive) bronchitis: 4.5% (95% CI: 4.3 to 
4.8) in the German population. Furthermore, diabetes 
was frequently reported for the fatal cases (17.2%) and 
doubled the risk of a fatal outcome (RR: 2.3; 95% CI: 
1.5 to 3.6). 
Two of the fatal cases were pregnant. One presented 
no other additional risk factor; the other was reported 
to be obese. Considering all pregnant women of 
Table 2
Underlying medical conditions of the first fatal cases of 2009 pandemic influenza A(H1N1) in adults ≥18 years, Germany, 
29 April 2009 to 31 March 2010 (n=196)
Underlying conditionsa Number of notifications in fatal cases (%)
Proportion in fatal cases as 
percentage (95% CI)




Yes 169 (100) 86.2 (80.6–90.7) 37.4 (36.8–38.1) 10.0 (6.7–15.0)
Immunosuppressiond 51 (30) 26.0 (20–32.7) NAe NA
Cardiovascular disease 46 (27.2) 23.5 (16.7–29.3) NA NA
Hypertension NA NA 21.4 (20.9–22.0) NA
Angina pectoris NA NA 1.7 (1.5–1.9) NA
Heart failure NA NA 2.4 (2.2–2.6) NA
Obesityf 39 (23.1) 19.9 (14.5–26.2) 13.4 (12.9–13.9) 1.2 (0.8–1.8)
Respiratory disease 39 (23.1) 19.9 (14.5–26.2) NA NA
Asthma NA NA 5.2 (4.9–5.5) NA
Chronic bronchitis NA NA 4.5 (4.3–4.8) NA
Diabetes 29 (17.2) 14.8 (10.1–20.6) 5.7 (5.4–6.0) 2.3 (1.5–3.6)
Pregnancy 2 (1.2) 1.0 (0.1–3.6) NA 2.2 (0.5–9.4)g
Other 50 (29.6) 25.5 NA NA
None 27 13.8 (9.3–19.4) NA NA
Total 196 100.0 NA NA
CI: confidence interval.
a Mutiple answers possible.
b German Health Update - Telephone Health Survey 2008/2009 (Germany) [16]. 
c Age- and sex-adjusted relative risk: risk in the exposed divided by the risk in the unexposed.
d Including three reported cases with leukaemia.
e NA= Not available
f Body mass index (BMI)>30 or being treated for obesity or international statistical classification of disease (ICD-10) Code E66 obesity 
(self-reported).
g Estimate for the relative risk of pregnancy: number of births in 2009: 682,514; population based on the female general population in women 
of child-bearing age (15–45 years): 16,129,518; corrected for the duration of pregnancy: 267 days and the days of the risk period: 338 days. 
Relative risk = 2 / 682,514 / 365 x 267 / 365 x 338 / 27 / 16,129,518.
Figure 2
Notified fatal cases of 2009 pandemic influenza A(H1N1) 
by time between symptom onset and start of antiviral 
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childbearing age in the general population at risk of 
infection, a rough estimate of the relative risk is possi-
ble. Taking 27 April 2009 as the start of the risk period, 
the relative risk was 2.2 (95% CI: 0.5 to 9.4). 
Discussion 
Disease frequency
The detailed analysis of notification data and risk fac-
tors in the general population of Germany presented in 
this paper gives insight into what might play a role in 
the differences between countries. Based on reported 
cases, the overall mortality in Germany of 3.1 (95% CI: 
2.7 to 3.5) per one million inhabitants is lower than that 
in North America – United States: 7.0 (95% CI: 6.7 to 
7.3) and Canada: 13.7 (95% CI: 12.4 to 15.1) and shows 
more similarities to that in other European countries. 
However, while in some neighbouring countries such 
as the Netherlands 3.7 (95% CI: 2.8 to 4.7), Belgium 
1.8 (95% CI: 1.1 to 2.8) and Austria: 4.8 (95% CI: 3.4 
to 6.5), the reported mortality was in the same range, 
Spain 6.3 (95% CI: 5.6 to 7.1), the United Kingdom 7.6 
(95% CI: 6.9 to 8.3) and France 5.1 (95% CI: 4.6 to 5.7) 
reported a substantial higher overall mortality than 
that observed in Germany. Special care should be 
taken when comparing and interpreting CFRs as the 
number of cases in the denominator is often difficult to 
estimate [3]. A right shift of the epidemic curve for fatal 
cases when compared with the non-fatal cases con-
tributing to an increase in CFR might suggests that the 
risk of severe outcome changed during the pandemic 
(Figure 1). We consider it more likely, however, that the 
affected age groups as well as the probability of labo-
ratory confirmation and reporting might have varied 
during the course of the pandemic wave. 
Age distribution of fatal cases
The population-based cumulative mortality in elderly 
people (≥60 years) was lower than that in adults aged 
35 to 59 years. However, this contrasts with the high-
est nCFR in the age group above 60 years and older. 
Serology data for pre-existing immunity from the 
United States, United Kingdom and Finland suggest 
that this might be the result of lower susceptibility of 
the oldest age group to an infection with the newly 
emerged influenza viral genotype, thus causing fewer 
cases [17-19]. Alternatively, age-dependent contact fre-
quency can become the driving force for an age-related 
distribution of cases, as studies on contact patterns 
show that the main contacts occur mostly within the 
same age strata [20]. 
Disease course
An intriguing observation has been the difference in 
the interval between onset of symptoms and death 
between children younger than 15 years and adults. 
This might suggest a frequent fulminant course of dis-
ease in children, despite the same frequency of hospi-
talisation and pneumonia in both groups. 
Antiviral treatment
In two thirds of the fatal cases, antiviral treatment was 
started after the 48-hour window following the onset 
of symptoms (Figure 2) and in half of the patients only 
after four days. This shows that some patients may 
not treated optimally, according to the recommenda-
tions for antiviral treatment [14]. On the other hand, 
the earlier treatment start reported for non-fatal cases 
suggests that specific antiviral treatment can reduce 
untoward outcome. Similar observations have been 
made in other countries [3,21]. 
Risk factors
It can be assumed that acute infection interacting with 
underlying chronic diseases plays a pivotal role in the 
outcome, as has been described by a number of stud-
ies on disease severity of pandemic influenza. Old and 
newly suggested risk factors, such as obesity, might 
also impair physiological mechanisms of compensation 
[22]. This is why it is important to report fatal cases of 
influenza virus infection even when the contribution of 
the infection to the detrimental course of disease can-
not be quantified precisely.
Most (86.2%) of the reported fatal cases in Germany 
had an increased likelihood of a severe disease course 
because of chronic illnesses, including a quarter of 
patients with more than one underlying disease con-
dition. The proportions of specific underlying condi-
tions vary between different countries or regions, with 
obesity most frequently observed in California (United 
States), neurological disorders in England and human 
immunodeficiency virus (HIV) infections in South Africa 
[2,3,7]. In our analysis we could show that the relative 
risk calculated on the basis of population data allows 
a more precise definition and ranking of risk groups, 
which might also allow for better comparison between 
countries. The fifth most frequent underlying disease, 
showing the highest estimate of risk in our study, was 
diabetes. As this condition is widely distributed in 
the European population it has probably been under-
estimated as a risk factor, so far and further research 
seems to be warranted. Other studies identified preg-
nancy as an important risk factor [23,24]. However, due 
to the small number of deaths in pregnant cases, our 
results are neither able to confirm nor exclude this for 
Germany.
Study limitations
Given the high disease awareness during the pandemic 
in the general population, among medical staff and the 
reporting authorities, it can be assumed that notified 
fatal cases with laboratory-confirmed pandemic influ-
enza present a good source of data for the elucidation of 
underlying medical conditions and other factors related 
with severe cases of this infection. Nevertheless, arte-
facts such as underreporting and misclassification of 
outcome or risk factors are possible and might conceal 
the real disease burden. Even though case-based infor-
mation on risk factors was also available for non-fatal 
cases, analysis showed that reporting was much more 
complete for patients who died. Therefore, we calcu-
lated the relative risk based on a self-reported popu-
lation survey. In addition, as notification of deaths is 
mandatory for laboratory-confirmed cases only, such 
deaths might represent only the tip of the iceberg, 
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since in the course of the pandemic wave it is estimated 
that fewer than every tenth case seen by a physician 
will be laboratory confirmed [25]. Information on other 
factors for the development of severe illness, such as 
infectious dose, general immune status (pre-existing 
immunity), nutrition, access to healthcare or unrecog-
nised comorbidity is lacking and might also influence 
the risk of death from pandemic influenza.
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